UroGen Pharma Ltd.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Sep 8, 2026+5.1
Trials
- URGNUroGen Pharma Ltd.5Calm
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
FinishedPhase 399 patientsMain results: Sep 11, 2025 - URGNUroGen Pharma Ltd.5Calm
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Signing up patientsPhase 370 patientsMain results: Mar 2027 - URGNUroGen Pharma Ltd.5Calm
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Running, no new patientsPhase 3240 patientsMain results: Apr 26, 2023
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
7 sales (5 not pre-planned) · 0 purchases
- Degnan ChrisChief Financial Officer · Oct 8, 2026Sold 2,202 sharesabout $81 thousand · not pre-planned
- Schoenberg MarkChief Medical Officer · Sep 8, 2026Sold 871 sharesabout $37 thousand · not pre-planned
- Smith Jason DrewGeneral Counsel · Sep 8, 2026Sold 1,519 sharesabout $65 thousand · not pre-planned
- Schoenberg MarkChief Medical Officer · Aug 20, 2026Sold 60,677 sharesabout $2.9 million · not pre-planned
- Schoenberg MarkChief Medical Officer · Jul 9, 2026Sold 10,000 sharesabout $400 thousand · pre-planned
- Schoenberg MarkChief Medical Officer · Jun 22, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.